aTyr Pharma, Inc. (LIFE) saw its loss widen to $13.82 million, or $0.58 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $11.33 million, or $0.48 a share.
The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $13.86 million, compared with an operating loss of $11.31 million in the previous year period.
"During the third quarter, we continued to make significant progress in our clinical development of ResolarisTM for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy 2B (LGMD2B). We look forward to announcing data from our three ongoing clinical trials in these indications next month," said John Mendlein, PhD, chief executive officer of aTyr Pharma. "We anticipate initiating clinical development for our iMod.Fc program for rare pulmonopathies next year. Finally, we continue to advance our understanding of the Resokine pathway to aid in therapeutically intervening in homeostatic pathways in a fiscally prudent manner."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
